MX2021006021A - Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. - Google Patents

Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.

Info

Publication number
MX2021006021A
MX2021006021A MX2021006021A MX2021006021A MX2021006021A MX 2021006021 A MX2021006021 A MX 2021006021A MX 2021006021 A MX2021006021 A MX 2021006021A MX 2021006021 A MX2021006021 A MX 2021006021A MX 2021006021 A MX2021006021 A MX 2021006021A
Authority
MX
Mexico
Prior art keywords
peptide
protein
present
immunogenicity
conjugate
Prior art date
Application number
MX2021006021A
Other languages
English (en)
Inventor
Sung Hee Park
Hyung Kyu Lim
In Young Choi
Seung Su Kim
Se Chang Kwon
Jae Hyuk Choi
Original Assignee
Hanmi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharma Co Ltd filed Critical Hanmi Pharma Co Ltd
Publication of MX2021006021A publication Critical patent/MX2021006021A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Vascular Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un procedimiento para aumentar la semivida en el suero de una proteína o péptido y para disminuir la inmunogenicidad del mismo por unión específica del sitio de un vehículo a una proteína o péptido, y al uso del mismo. El conjugado de la proteína o péptido fisiológicamente activo de la presente invención puede disminuir significativamente la inmunogenicidad en el cuerpo humano y por lo tanto reducir la tasa de producción de anticuerpos contra la proteína o péptido. Por lo tanto, el presente conjugado tiene la ventaja de que el fenómeno de reducción de los efectos clínicos de la proteína o péptido fisiológicamente activo es bajo, y puede utilizarse eficazmente en el desarrollo de formulaciones de acción prolongada para que tengan una alta seguridad contra la respuesta inmunitaria.
MX2021006021A 2014-06-05 2016-11-29 Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. MX2021006021A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140068660A KR20150140177A (ko) 2014-06-05 2014-06-05 단백질 및 펩타이드의 면역원성을 감소시키는 방법

Publications (1)

Publication Number Publication Date
MX2021006021A true MX2021006021A (es) 2021-07-06

Family

ID=54767003

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016015668A MX2016015668A (es) 2014-06-05 2015-06-05 Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
MX2021006021A MX2021006021A (es) 2014-06-05 2016-11-29 Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016015668A MX2016015668A (es) 2014-06-05 2015-06-05 Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.

Country Status (20)

Country Link
US (2) US20170100488A1 (es)
EP (2) EP3152236A4 (es)
JP (2) JP7125249B2 (es)
KR (3) KR20150140177A (es)
CN (1) CN106661118A (es)
AR (1) AR100768A1 (es)
AU (1) AU2015269039B2 (es)
BR (1) BR112016028227A2 (es)
CA (1) CA2950576A1 (es)
EA (1) EA035964B1 (es)
HU (1) HUP1700024A2 (es)
IL (1) IL249131A0 (es)
MX (2) MX2016015668A (es)
MY (1) MY193519A (es)
NO (1) NO20161980A1 (es)
PH (1) PH12016502430A1 (es)
SG (2) SG10202104313PA (es)
TW (1) TW201625314A (es)
UA (1) UA124183C2 (es)
WO (1) WO2015186988A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CN106488933A (zh) * 2014-03-31 2017-03-08 韩美药品株式会社 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
WO2018017923A1 (en) * 2016-07-22 2018-01-25 Nektar Therapeutics Conjugates of a factor viii moiety having an oxime-containing linkage
CN110291103A (zh) * 2016-12-05 2019-09-27 韩美药品株式会社 具有弱化的免疫应答的缀合物
US20200230250A1 (en) * 2017-02-03 2020-07-23 Hanmi Pharm. Co., Ltd. Long-acting conjugate of a physiologically active material and use thereof
EP3668640A4 (en) * 2017-08-18 2021-07-14 The Johns Hopkins University SUPRAMOLECULAR FILAMENTOUS ASSEMBLIES FOR PROTEIN PURIFICATION
WO2019040674A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc SOLUBLE INTERFERON RECEPTORS AND USES THEREOF
CN111406073A (zh) * 2017-09-29 2020-07-10 韩美药品株式会社 具有提高功效的持久性蛋白质缀合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CN1414971A (zh) * 1999-12-08 2003-04-30 埃克斯西特治疗公司 用作免疫抑制剂的缩肽及其同类物
CN1507357A (zh) * 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
JP2004532620A (ja) * 2001-02-19 2004-10-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 免疫原性の低減された人工タンパク質
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2008130066A1 (en) * 2007-04-20 2008-10-30 Kang Choon Lee Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
WO2010107256A2 (en) * 2009-03-20 2010-09-23 Hanmi Pharm. Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
AU2012267398B2 (en) 2011-06-10 2016-10-13 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
JP2012256007A (ja) 2011-06-10 2012-12-27 Nippon Zeon Co Ltd パターン位相差フィルム用液晶組成物、パターン位相差フィルム及び立体表示装置
RU2733544C2 (ru) 2011-06-17 2020-10-05 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
SG10201907106VA (en) 2013-02-26 2019-09-27 Hanmi Pharmaceutical Co Ltd Novel insulin analog and use thereof
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법

Also Published As

Publication number Publication date
PH12016502430A1 (en) 2017-03-06
UA124183C2 (uk) 2021-08-04
EA035964B1 (ru) 2020-09-07
KR20230023691A (ko) 2023-02-17
KR20150140177A (ko) 2015-12-15
SG10202104313PA (en) 2021-06-29
NO20161980A1 (en) 2016-12-14
JP2017521381A (ja) 2017-08-03
EP3152236A1 (en) 2017-04-12
SG11201610098YA (en) 2016-12-29
JP2021028329A (ja) 2021-02-25
BR112016028227A2 (pt) 2017-10-24
CN106661118A (zh) 2017-05-10
WO2015186988A1 (en) 2015-12-10
KR20210111190A (ko) 2021-09-10
CA2950576A1 (en) 2015-12-10
EP3152236A4 (en) 2018-07-04
MX2016015668A (es) 2017-02-27
TW201625314A (zh) 2016-07-16
US20220118103A1 (en) 2022-04-21
AU2015269039B2 (en) 2020-12-10
IL249131A0 (en) 2017-01-31
US20170100488A1 (en) 2017-04-13
JP7125249B2 (ja) 2022-08-24
MY193519A (en) 2022-10-17
AU2015269039A1 (en) 2016-12-08
HUP1700024A2 (en) 2017-05-29
AR100768A1 (es) 2016-11-02
EP4219565A1 (en) 2023-08-02
EA201692279A1 (ru) 2017-05-31

Similar Documents

Publication Publication Date Title
PH12016502430A1 (en) Method for decreasing immunogenicity of protein and peptide
AU2018260800B2 (en) Hepcidin analogues and uses therof
MY193249A (en) Anti-human cd19 antibodies with high affinity
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MX2019009660A (es) Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna.
NZ705370A (en) Fcγriib-specific fc region variant
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
MX2016014414A (es) Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
MY174991A (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
MX2017003121A (es) Formulaciones de anticuerpos.
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2017008406A (es) Conjugados de aminoacidos y peptidos y sus usos.
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
MX2017001176A (es) Terapia de combinacion.
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
IN2014DN09445A (es)
MX2019006446A (es) Métodos para inducir tolerancia inmunológica a factores de coagulación.
MX2019003258A (es) Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana.
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
WO2014172309A3 (en) Therapeutic compositions for neutralizing type i interferons, and methods of use
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.